-
CD20 CAR-T therapy ORR reaches 100%, and CAR-T at home and abroad may usher in a wave of listing
Time of Update: 2022-11-04
October 31, 2022 /eMedClub News/--Bio, a biopharmaceutical company, recently announced the latest Phase 1/2 clinical trial of its CD20-targeted CAR-T therapy MB-106 for the treatment of multiple hematological tumors, the results of which will be presented at the 11th International Symposium on Waldenstrom Macroglobulinemia 。 MB-106 is a fully human, third-generation, CD20-targeted CAR-T cell therapy containing 4-1BB and CD28 co-stimulatory domains, and its modified IgG1 spacer eliminates FcR binding.
-
JHO: Dara-DCEP treatment with extramedullary lesions RRMM, ORR 67.7%, PFS 5 months
Time of Update: 2022-11-04
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
The study flow is shown in Figure 1A, where patients receive 3 cycles of DARA-DCEP induction therapy, followed by 5 cycles of DARA maintenance therapy.
-
ESMO field direct osimertinib "induces" stage III unresectable NSCLC with an ORR of 94%!
Time of Update: 2022-11-01
At this year's ESMO conference, a study explored the efficacy of osimertinib induction therapy in patients with EGFR-sensitive mutation stage III unresectable patients.
At this year's ESMO conference, a study explored the efficacy of osimertinib induction therapy in patients with EGFR-sensitive mutation stage III unresectable patients.
-
TCR-T therapy ORR up to 80%! In the field of solid tumors, CAR-T/NK and TIL each show their powers
Time of Update: 2022-10-20
October 12, 2022 / eMedClub News / -- On October 10, Immatics announced the results of its latest clinical trial of IMA203, a TCR-T therapy targeting the PRAME antigen 。 Overall, IMA203 is well tolera
-
SOHO 2022: Zebrutinib has better ORR and PFS benefits than ibrutinib in patients with relapsed/refractory CLL/SLL disease
Time of Update: 2022-10-19
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
-
With Dostarlimab's "head-to-head" K drug, GSK announced that the PERLA study reached the primary endpoint of ORR
Time of Update: 2022-10-13
On 5 October, GSK announced that its PD-1 monoclonal antibody Jemperli (dostarlimab) combined with chemotherapy head-to-head comparison of Keytruda plus chemotherapy first-line therapy for metastatic non-squamous non-small cell lung cancer (NSCLC) Phase II PERLA trial achieved positive results, reaching the objective response rate (ORR) primary endpoint.
-
ESMO on-site direct attack After the progression of ositinib, ositinib combined treatment "re-challenge", fast response within 6 weeks, ORR exceeded 50%
Time of Update: 2022-10-03
Details are as follows: Professor Julien Mazieres 1 Background There is a lack of optimal treatment options after first-line ositinib therapy with advanced NSCLC of EGFR-sensitive mutations, and there is still a high degree of unmet clinical need.
-
ESC 2022: First Phase III Results of Targeted KRAS G12C Sotorasib for NSCLC Released with an ORR of 28.1%
Time of Update: 2022-10-02
Gritstone Presents Positive Initial Phase 2 Data in Late-Line Solid Tumor Patients Treated With KRAS-Directed Immunotherapy (SLATE) at ESMO 2022 | Gritstone bio KRAS is the most common oncogene, with mutations in a variety of cancers (common cancers such as colon and lung, bile duct, small bowel, skin, bladder and breast, with a rate of pancreatic cancer mutations up to 90%).
-
Professor Liu Tianshu: The ORR is as high as 42%, and the T-DXd second-line treatment of HER2+ advanced gastric cancer has begun to appear
Time of Update: 2022-10-01
How do you see the value of DG02 research in the breakthrough of HER2+ advanced GC second-line therapy?Professor Liu TianshuThe DG02 trial is an open-label, multicenter Phase II clinical study designed to evaluate the efficacy and safety of T-DXd in HER2+ advanced GC/GEJC with disease progression following trastuzumab therapy.
-
ESMO directly hit Belzutifan, VHL-associated renal cell carcinoma ORR reached 64%
Time of Update: 2022-09-21
The Phase II LITESPARK-004 study published results from a 3-year follow-up of belzutifan in the treatment of VHL-related RCCs. methodAdult patients who are eligible (germ cell VHL mutation, non-metastatic RCC measurable lesion ≥1, RCC lesion without >3 cm requiring immediate surgery, previous systemic antineoplastic therapy, ECOG PS 0-1) are treated with belzutifan (120 mg once daily) until disease progression, intolerable toxicity occurs, or the patient withdraws consent.
-
ESMO Direct Hit ORR 42.2% and DCR 75.6%! Preliminary results of a Phase I study on the treatment of relapsed refractory B-NHL by TRS005 were published
Time of Update: 2022-09-21
Professor Shi Yuankai's team at the Cancer Hospital of the Chinese Academy of Medical Sciences conducted a Phase I dose escalation and extension study (CTR20182204) to explore the safety, pharmacokinetics and preliminary efficacy of TRS005 in patients with CD20+ relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
-
Express ORR up to 59.8%! Di zhe pharmaceutical suvotinib lung cancer registration study reached the main endpoint
Time of Update: 2022-09-14
▲If you have any business needs, please long press to scan the QR code above, or▎ WuXi AppTec content team reportsRecently, Di zhe Pharmaceutical announced that the first registered study of suvotinib in patients with advanced non-small cell lung cancer (NSCLC) who had previously received platinum chemotherapy and carried EGFR exon20ins had reached the main endpoint.
-
JCO: Immunocombination therapy improves OS and ORR in advanced sarcomas and solid tumors
Time of Update: 2022-09-09
Download the Doctor Station App and subscribe anytime, anywhere~*For medical professional reading reference only1 minute a day, give you professional "talks" in the tumor circle!
Download the Doctor Station App and subscribe anytime, anywhere~*For medical professional reading reference only1 minute a day, give you professional "talks" in the tumor circle!
-
One-arm trial + ORR may not be enough?
Time of Update: 2022-06-07
On April 14, Nicholas, an officer of the FDA Oncology Center of Excellence (OCE), and others published an article in The Lancet-Oncology: The development program of PI3K inhibitors in hematological malignancies highlights the challenges associated with the current paradigm of using overall response rate (ORR) in single-arm trials to support accelerated approval .
-
ORR 92.86%!
Time of Update: 2022-06-06
On this occasion, Yimaitong specially invited Professor Ma Jun from the Harbin Institute of Hematology and Oncology to interpret the updated highlights of the new "CSCO Lymphoma Diagnosis and Treatment Guidelines" and the application of sapalizumab .